A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized. Precision’s Maureen Hennessey shares the survey data and offers observations and suggestions for opportunities for plans, delivery systems, and pharmaceutical manufacturers to address the mental health and substance use epidemics occurring within the COVID pandemic.

Read the full article here!